Develops cannabinoid-based therapies for pain management and neurological disorders, focusing on novel pharmaceutical approaches.
SciSparc Ltd., a specialized clinical-stage pharmaceutical company, focuses on advancing therapeutic treatments utilizing cannabinoid molecules. The company's robust drug development pipeline includes SCI-110, designed for addressing Tourette syndrome, obstructive sleep apnea, and Alzheimer's disease-related agitation. Additionally, SCI-160 is targeted at managing pain, while SCI-210 aims to tackle conditions such as autism spectrum disorder and epilepsy. SciSparc collaborates extensively to enhance its development capabilities, partnering with Procaps for the commercial production of SCI-110 and CannAmide, a palmitoylethanolamide oral tablet in soft gel capsule form.
Through strategic alliances, SciSparc is poised to expand its therapeutic portfolio significantly. Collaborations with the Sheba Fund for Health Services and Research and The Israeli Medical Center for Alzheimer's exemplify the company's commitment to exploring novel applications for SCI-210, particularly in treating status epilepticus and conducting phase IIa clinical trials for Alzheimer's disease and agitation with SCI-110. Formerly known as Therapix Biosciences Ltd., the company rebranded as SciSparc Ltd. in January 2021, reflecting its evolution and focus in the pharmaceutical landscape.
Founded in 2004 and headquartered in Tel Aviv-Yafo, Israel, SciSparc Ltd. continues to pioneer advancements in cannabinoid-based therapies, leveraging its scientific expertise and strategic partnerships to address critical medical needs globally.